Beta-amyloid peptide (A-beta) is the primary protein component of senile plaques in Alzheimer's disease (AD) patients. A-beta assembles into amyloid fibrils of 5-10 nm diameter, characterized by cross-beta conformation and birefringence upon Congo red staining. A-beta is toxic to neuronal cultures, and there is growing evidence that deposition of A-beta fibrils is central to the development of AD pathology. neurotoxicity of A-bet may require that the peptide adopt specific aggregational and/or conformational states. Despite this apparently obligatory requirement of fibrillogenesis to render A-beta toxic, the details of the A-beta assembly process and the fundamental role that A-beta assembly plays in A-beta-mediated neurotoxicity are still uncertain. There is some evidence that A-beta aggregation plays a significant role in binding of A-beta to cellular membranes, and that this binding is a key element in A-beta-mediated neurotoxicity. Substantial industrial and academic research effort is currently aimed towards identifying molecules which disrupt A-beta aggregation and, presumably, A-beta neurotoxicity. This process would be greatly aided by a more fundamental understanding of A-beta assembly and disassembly pathway and kinetics, and the role of aggregation in A-beta interactions with cells. The proposed project has two specific aims.
Specific aim 1 : A detailed mechanistic model of A-beta assembly and disassembly kinetics will be developed. To accomplish this, a series of experiments will be conducted to measure the rates of change in secondary structure, fibril length, and fibril number concentration, and the data will be used to construct and validate a quantitative mathematical model of A-beta assembly kinetics.
Specific aim 2 : Short peptides with partial homology to the central sequence of A-beta will be characterized for their ability to modulate A-beta aggregation kinetics and A-beta cytotoxicity. Several such peptides have already been synthesized; some of these peptides have been shown to alter A-beta aggregation kinetics or fibril changes in aggregation state to changes in cytotoxicity. Additionally, these short peptides may provide lead compounds for further development of therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG014079-02
Application #
6016809
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Project Start
1998-06-01
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Kim, Jin Ryoun; Muresan, Adrian; Lee, Ka Yee C et al. (2004) Urea modulation of beta-amyloid fibril growth: experimental studies and kinetic models. Protein Sci 13:2888-98
Kim, Jin Ryoun; Murphy, Regina M (2004) Mechanism of accelerated assembly of beta-amyloid filaments into fibrils by KLVFFK(6). Biophys J 86:3194-203
Kremer, John J; Murphy, Regina M (2003) Kinetics of adsorption of beta-amyloid peptide Abeta(1-40) to lipid bilayers. J Biochem Biophys Methods 57:159-69
Pallitto, M M; Murphy, R M (2001) A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. Biophys J 81:1805-22
Kremer, J J; Sklansky, D J; Murphy, R M (2001) Profile of changes in lipid bilayer structure caused by beta-amyloid peptide. Biochemistry 40:8563-71
Kremer, J J; Pallitto, M M; Sklansky, D J et al. (2000) Correlation of beta-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 39:10309-18
Murphy, R M; Pallitto, M M (2000) Probing the kinetics of beta-amyloid self-association. J Struct Biol 130:109-22